Gary Piazza

Company: Auburn University

Job title: Chief Scientist, ADT Pharmaceutical & Professor

Seminars:

Debunking Safety & Efficacy Concerns Surrounding Targeting Wild Type KRAS to Induce Tumor Regression 8:30 am

Wild type KRAS continues to present a huge challenge in selectively targeting mutant variants implicated in cancer due to its structural similarity and essential cellular functions. Debate surrounds the feasibility and safety of directly targeting wild type KRAS, with concerns over potential off-target effects. Despite advances in structural and functional studies, these findings are yet…Read more

day: Workshop A

Exploring Mechanisms of Action & Navigating Agent Synergy in the Pre-clinic to Improve the Efficacy of Combination Therapies 2:30 pm

Current pre-clinical exploration in combination strategies for targeting RAS-driven tumors is underscored by selecting synergistic agents with complementary mechanisms to overcome acquired resistance. Amidst the emergence of diverse modalities, a deeper understanding of the interplay between targeted proteins and up/downstream pathways is crucial, alongside toxicity risks. This workshop will shed light on promising combinations in…Read more

day: Workshop E